NVTA NYSE
Invitae Corporation
1W: -3.6%
1M: -11.1%
3M: -97.2%
1Y: -99.0%
3Y: -100.0%
5Y: -99.9%
$0.02
Last traded 2024-03-11 — delisted
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
No convergence signal
Key Statistics
Market Cap$5.4M
52W Range0.015-2.34
Volume22,459,258
Avg Volume12,849,005
Beta1.59
Dividend—
Analyst Ratings
Company Info
CEOKenneth D. Knight
Employees1,700
SectorHealthcare
IndustryMedical - Diagnostics & Research
IPO Date2015-02-12
Websiteinvitae.com
1400 16th Street
San Francisco, CA 94103
US
San Francisco, CA 94103
US
415 374 7782
About Invitae Corporation
Invitae Corporation, a medical genetics company, integrates genetic information into mainstream medicine to improve healthcare of people in the United States, Canada, and internationally. The company offers genetic tests in various clinical areas, including hereditary cancer, cardiology, neurology, pediatrics, oncology, metabolic conditions, and rare diseases; digital health solutions; and health data services. It serves patients, healthcare providers, biopharma companies, and other partners. The company was formerly known as Locus Development, Inc. and changed its name to Invitae Corporation in 2012. Invitae Corporation was incorporated in 2010 and is headquartered in San Francisco, California.
Latest News
No recent news
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Nussbaum Robert L | F-InKind | 17,404 | $0.65 | 2023-12-20 |
| Brida Thomas | F-InKind | 17,404 | $0.65 | 2023-12-20 |
| Sholehvar David | A-Award | 850,000 | — | 2023-11-13 |
| Sholehvar David | 0 | — | 2023-11-13 | |
| Brida Thomas | A-Award | 229,500 | — | 2023-10-18 |